 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
OBJECTIVE: To examine the pharmacology, therapeutics, pharmacokinetics, dosing guidelines, adverse effects, and drug interactions of insulin aspart, and summarize the clinical trials of efficacy and safety in patients with type or type 2 diabetes mellitus. DATA SOURCES: A MEDLINE database search (1985-May 2000) was performed to identify all applicable published articles and abstracts; in some cases, Novo Nordisk unpublished information was also obtained. Review articles on insulin analogs were also identified, as well as review chapters in medical textbooks. STUDY SELECTION: The majority of the studies identified were in abstract form. These studies reported information on the pharmacokinetics of insulin aspart in healthy volunteers and in those with diabetes, as well as the therapeutic utility, safety, and clinical efficacy in patients with diabetes. A limited number of randomized studies were reported as artices in the medical literature DATA EXTRACTION: All published clinical studies were reviewed. DATA SYNTHESIS: Insulin aspart, the second Food and Drug Administration-approved rapid-acting insulin analog, is produced by recombinant technology that replaces the proline at position 28 on the B chain of insulin with negatively charged aspartic acid. Insulin aspart exists as hexamers that rapidly dissociate into monomers and dimers on subcutaneous injection. When administered immediately prior to a meal, insulin aspart is at least as effective as regular human insulin in control of postprandial blood glucose concentrations. Insulin aspart achieves higher peak insulin concentrations in less time and with a shorter duration of action than regular human insulin. CONCLUSIONS: Insulin aspart is a convenient premeal insulin for use by patients requiring mealtime insulin. Furthermore, due to favorable pharmacokinetics, insulin aspart controls postprandial blood glucose concentrations at least as well as regular human insulin and contributes to improved quality of life.
This article has been cited by other articles:
|
|
 |
|
  F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]
|
|
|
|
 |
|
 X. JiXiong, L. Jianying, C. Yulan, and C. Huixian The Human Insulin Analog Aspart Can Induce Insulin Allergy Diabetes Care, August 1, 2004; 27(8): 2084 - 2085. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Abrahamson Optimal Glycemic Control in Type 2 Diabetes Mellitus: Fasting and Postprandial Glucose in Context Arch Intern Med, March 8, 2004; 164(5): 486 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Pettitt, P. Ospina, J. W. Kolaczynski, and L. Jovanovic Comparison of an Insulin Analog, Insulin Aspart, and Regular Human Insulin With No Insulin in Gestational Diabetes Mellitus Diabetes Care, January 1, 2003; 26(1): 183 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Airaghi, M. Lorini, and A. Tedeschi The Insulin Analog Aspart: A Safe Alternative in Insulin Allergy Diabetes Care, November 1, 2001; 24(11): 2000 - 2000. [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
